Combination therapy for cognitive and emotional impairments in patients with arterial hypertension
Abstract
The paper deals with the problem of cognitive and emotional impairments (CI and EI) in patients with arterial hypertension (AH). It stresses the importance of their correction to improve adherence to treatment. The mechanisms of action and clinical efficacy of standardized Ginkgo biloba extract (Egb 761®) and the results of its trials are discussed. The paper describes a clinical case illustrating the efficacy and safety of the drug in a female patient with AH, CI, and EI.
About the Authors
O. D. Ostroumova
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
20, Delegatskaya St., Build. 1, Moscow 127473
11, Rossolimo St., Moscow 119021
E. A. Karavashkina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
11, Rossolimo St., Moscow 119021
Russian Federation
11, Rossolimo St., Moscow 119021
References
1. World Health Organization. Cardiovascular diseases (CVDs). Fact sheet. Reviewed June 2016, cited 2016-08-26. http://www.who.int/mediacentre/factsheets/fs317/en/
2. Чазова ИЕ, Ратова ЛГ, Бойцов СА, Небиеридзе ДВ. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010;(3):5-26. [Chazova IE, Ratova LG, Boitsov SA, Nebieridze DV. Diagnosis and treatment of hypertension (Recommendations of the Russian medical society on arterial hypertension and Russian scientific society of cardiology). Sistemnye gipertenzii. 2010;(3):5-26. (In Russ.)].
3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.
4. Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in middle-age in the Whitehall II study. J Clin Epidemiol. 2005 Dec;58(12):1308-15.
5. Парфенов ВА, Старчина ЮА. Когнитивные нарушения у пациентов с артериальной гипертензией и их лечение. Неврология, нейропсихиатрия, психосоматика. 2011;3(1):27-33. [Parfenov VA, Starchina YuA. Cognitive disorders in patients with essential hypertension and their treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(1):27-33. (In Russ.)]. DOI: 10.14412/2074-2711-2011-130
6. Старчина ЮА, Парфенов ВА, Чазова ИЕ и др. Когнитивные расстройства у пациентов с артериальной гипертензией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;(4):39–43. [Starchina YuA, Parfenov VA, Chazova IE, et al. Cognitive disorders in patients with arterial hypertension. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008; (4):39–43. (In Russ.)].
7. Филатова ЕГ, Наприенко МВ. Терапия нарушений памяти и внимания у молодых пациентов. Неврология, нейропсихиатрия, психосоматика. 2013;5(3):18-23. [Filatova EG, Naprienko MV.Therapy for memory and attention impairments in young patients. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psichosomatics. 2013;5(3):18–23. (In Russ.)]. DOI: 10.14412/2074-2711-2013-2334
8. Преображенская ИС. Легкие и умеренные когнитивные нарушения – клинические проявления, этиология, патогенез, возможности использования ноотропной терапии. Фарматека. 2013; (s4-13):14-8. [Preobrazhenskaya IS. Light and moderate cognitive disorders – clinical manifestations, etiology, pathogenesis, the possibility of using nootropic therapy. Farmateka. 2013;(s4-13): 14-8. (In Russ.)].
9. Старчина ЮА, Парфенов ВА, Чазова ИЕ и др. Когнитивные функции и эмоциональное состояние больных, перенесших инсульт, на фоне антигипертензивной терапии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2005;(15):39–44. [Starchina YuA, Parfenov VA, Chazova IE, et al. Cognitive function and emotional status of stroke patients on the background of antihypertensive therapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2005;(15):39–44. (In Russ.)].
10. Старчина ЮА. Ранняя диагностика и лечение когнитивных расстройств при артериальной гипертензии. Дисc. канд. мед. наук. Москва; 2006. [Starchina YuA. Early diagnosis and treatment of cognitive disorders in arterial hypertension. Diss. cand. med. sci. Moscow; 2006].
11. Международная статистическая классификация болезней и проблем, связанных со здоровьем, 10-й пересмотр. Т. 1. Москва: Медицина; 1995. 765 c. [International statistical classification of diseases and health-related problems, 10th revision. Vol. 1. Moscow: Meditsina; 1995. 765 p].
12. Захаров ВВ, Локшина АБ. Ведение пациентов с когнитивными нарушениями. Москва, 2007. 30 с. [Zakharov VV, Lokshina AB. Vedenie patsientov s kognitivnymi narusheniyami. Moscow, 2007. 30 р].
13. Grylewski RJ, Korbut R, Robak J, Swies J. On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol. 1987 Feb 1;36(3):317-22.
14. Hofferberth B. Influence of Gingo biloba extract (EGb761) on neurophysiological and neuropsychological measurements in patients suffering from psychoorganic syndrome. In: Christen Y, Courtois Y, Droy- Lefaix MT, editors. Effects of Gingo biloba extract (EGb761) on aging and age-related disorders. Advances in Gingo biloba Extract Research. Paris: Elservier; 1995. P. 141-8.
15. Rapin JR, Franchert S, Grieu R. Effect of EGb761 on drain acetylcholine turnover. In.: De Feudis FV, editor. Gingo biloba extract (EGb761). Pharmacological activities and clinical application. Paris: Elservier; 1987. 17/18:2-12.
16. Taylor J. In vitro interaction of EGb761 with biogenic amine uptake sites and NMDA receptors syndrome. In: ChristenY, Courtois Y, Droy-Lefaix MT, editors. Effects of Gingo biloba extract (EGb761) on aging and age- related disorders. Advances in Gingo biloba Extract Research. Paris: Elservier; 1995. 4:1-6.
17. Brondino N, De Silvestri A, Re S, et al. A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine. Evid Based Complement Alternat Med. 2013;2013:915691. doi: 10.1155/2013/915691. Epub 2013 May 28.
18. DeFeudis FV, Drieu K. Ginkgo Biloba Extract (EGb 761®) and CNS Functions: Basic Studies and Clinical Applications. Curr Drug Targets. 2000 Jul;1(1):25-58.
19. Cieza A, Maier P, Pö ppel E. The effect of ginkgo biloba on healthy elderly subjects. Fortschr Med Orig. 2003;121(1):5-10.
20. Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761® in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, doubleblind, placebo-controlled trial. J Psychiatr Res. 2007 Sep;41(6):472-80. Epub 2006 Jun 30.
21. Jezova D, Duncko R, Lassanova M, et al. Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EGB 761®) in healthy volunteers. J Physiol Pharmacol. 2002 Sep; 53(3):337-48.
22. Краснов ВН, Вельтищев ДЮ. Неврастения как вариант астенического синдрома: фармакотерапевтический анализ на модели терапии Tанаканом. Журнал неврологии и психиатрии им. С.С. Корсакова. 1999;99(7):37-40. [Krasnov VN, Vel'tishchev DYu. Neurasthenia as a variant of the asthenic syndrome: pharmacological analysis of a model of therapy with Tanakan. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 1999;99(7):37-40. (In Russ.)].
23. Милопольская ИМ. Лечение Танаканом астенических расстройств. Терапевтический архив. 2001;73(10):45-7. [Milopol'skaya IM. Treatment of asthenic disorders with Tanakan. Terapevticheskii arkhiv. 2001;73(10):45-7. (In Russ.)].
24. Незнамов ГГ, Телешова ЕС, Сюняков СА и др. Влияние танакана на психофизиологическое состояние больных с астеническими расстройствами. Экспериментальная и клиническая психофармакология. 2002;65(1):22-8. [Neznamov GG, Teleshova ES, Syunyakov SA, et al. Effect of tanakan on the psychophysiological state of patients with asthenic disorders. Eksperimental'naya i klinicheskaya psikhofarmakologiya. 2002;65(1):22-8. (In Russ.)].
25. Незнамов ГГ, Сюняков СА, Давыдова ИА, Телещова ЕС. «Быстрые» и «медленные» компоненты психотропного действия препаратов с ноотропными свойствами. Журнал неврологии и психиатрии им. С.С. Корсакова. 2000;100(6):33-7. [Neznamov GG, Syunyakov SA, Davydova IA, Teleshchova ES. «Fast» and «slow» components of psychotropic action of drugs with nootropic properties. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2000;100(6):33-7. (In Russ.)].
26. Незнамов ГГ, Давыдова ИА, Кошелев ВВ и др. Перспективы применения Танакана в качестве антиастенического средства. Социальная и клиническая психиатрия. 1999; (2):21-6. [Neznamov GG, Davydova IA, Koshelev VV, et al. Prospects for the use of Tanakan as antiasthenic drug. Sotsial'naya i klinicheskaya psikhiatriya. 1999;(2):21-6. (In Russ.)].
27. Парфенов ВА, Старчина ЮА. Лечение танаканом неврологических расстройств у больных с артериальной гипертензией. Русский Медицинский Журнал. 2005;(22):1462- 5. [Parfenov VA, Starchina YuA. Tanakan in the treatment of neurological disorders in patients with arterial hypertension. Russkii Meditsinskii Zhurnal. 2005;(22):1462-5. (In Russ.)].
28. Парфенов ВА, Cоловьева ЭЮ, Антоненко ЛМ и др. Лечение комбинированных когнитивных и эмоциональных расстройств у больных молодого и среднего возраста. Неврология, нейропсихиатрия, психосоматика. 2016;8(2):17-23. [Parfenov VA, Solov'eva EYu, Antonenko LM, et al. Treatment for mixed cognitive impairments and emotional disorders in young and middle-aged patients. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2016;8(2):17-23. (In Russ.)]. DOI: 10.14412/2074-2711-2016-2-17-23
29. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70.
30. Остроумова ОД. Вариабельность артериального давления и риск развития инсульта при гипертонической болезни. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(10):45-50. [Ostroumova OD. Blood pressure variability and risk of stroke in hypertension. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(10):45- 50. (In Russ.)].
31. Verdecchia P, Angeli F, Gattobigio R, et al. Impact of Blood Pressure Variability on Cardiac and Cerebrovascular Complications in Hypertension. Am J Hypertens. 2007 Feb;20(2):154-61.
32. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010 Mar 13;375(9718):895-905. doi: 10.1016/S0140-6736(10)60308-X.
33. Fratolla A, Parati G, Guspidi C, et al. Prognostic value of 24-hour pressure variability. J Hypertens. 1993 Oct;11(10):1133-7.
34. Parati G, Ulian L, Santucciu C, et al. Blood pressure variability, cardiovascular risk and antihypertensive treatment. J Hypertens Suppl. 1995 Dec;13(4):S27-34.
35. Dolan E, Stantonb AV, Thomc S, et al on behalf of the ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens. 2009 Apr;27(4): 876-85. doi: 10.1097/HJH.0b013e328322cd62.
36. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005 Jul;46(1):156-61. Epub 2005 Jun 6.
37. 2013 Ambulatory Blood Pressure Monitoring Recommendations for the diagnosis of Adult Hypertension, Assessment of Cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int. 2013 Apr;30(3):355-410. doi: 10.3109/07420528.2013.750490.
38. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day vs. night ambulatory blood pressure: a cohort study. Lancet. 2007 Oct 6;370(9594):1219-29.
39. Fagard RH, Thijs L, Staessen JA, et al. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens. 2009 Oct;23(10):645-53. doi: 10.1038/jhh.2009.9. Epub 2009 Feb 19.
40. Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure: the Ohasama study. J Hypertens. 2002 Nov;20(11):2183-9.
41. Pierdomenico S, Bucci A, Costantini F, et al. Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease. J Am Coll Cardiol. 1998 Jun;31(7):1627-34.
42. Cuspidi C, Macca G, Sampieri L, et al. Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J Hypertens. 2001 Sep;19(9):1539-45.
43. Guo H, Tabara Y, Igase M, et al. Abnormal nocturnal blood pressure profile is associated with mild cognitive impairment in the elderly: the J-SHIPP study. Hypertens Res. 2010 Jan;33(1):32-6. doi: 10.1038/hr.2009.172. Epub 2009 Oct 23.
Review
For citations:
Ostroumova O.D., Karavashkina E.A. Combination therapy for cognitive and emotional impairments in patients with arterial hypertension. Neurology, Neuropsychiatry, Psychosomatics. 2017;9(1):84-89. (In Russ.) https://doi.org/10.14412/2074-2711-2017-1-84-89
Views: 418
Email this article 